目次

Table of Content

1. Introduction To KRAS Inhibitors
1.1 Development Of KRAS Inhibitors
1.2 Mechanism Of Action

2. Role Of KRAS Inhibitors In Cancer Therapy

3. Global KRAS Inhibitor Market Outlook
3.1 Current Market Scenario
3.2 KRAS Inhibitors Granted Breakthrough Therapy, Fast Track and Orphan
Designation
3.3 Future Market Opportunity

4. Lumakras - Overview, Pricing, Dosing and Sales Analysis
4.1 Overview and Patent Insight
4.2 Dosage and Price Analysis
4.3 Sales Analysis

5. Krazati - Overview, Pricing, Dosing and Sales Analysis
5.1 Overview and Patent Insight
5.2 Dosage and Price Analysis
5.3 Sales Analysis

6. Dupert - Clinical Insight

7. Anfangning - Clinical Insight

8. KRAS Inhibitor Market Regional Analysis - Commercial and Clinical Development Outlook
8.1 US
8.2 China
8.3 EU
8.4 UK
8.5 Japan
8.6 South Korea
8.7 Canada
8.8 Taiwan
8.9 Australia

9. KRAS Inhibitor Development Trends By Indications
9.1 Lung Cancer
9.2 Colorectal Cancer
9.3 Pancreatic Cancer
9.4 Other Indications

10. Global KRAS Inhibitors Clinical Pipeline Overview
10.1 By Country
10.2 By Phase
10.3 By Company
10.4 By Indication
10.5 By Priority Status

11. Global KRAS Inhibitor Clinical Trials Insight By Country, Company, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Phase I
11.4 Phase I/II
11.5 Phase II
11.6 Phase III
11.7 Preregistration
11.8 Registered

12. Marketed KRAS Inhibitor Clinical Trials Insight

13. KRAS Inhibitors Combination Strategies
13.1 Immunotherapy
13.2 Chemotherapy
13.3 Targeted Therapies
13.4 Radiation

14. Global KRAS Inhibitors Market Dynamics
14.1 Market Drivers
14.2 Market Challenges

15. Competitive Landscape
15.1 Applied Pharmaceutical Science
15.2 Amgen
15.3 AnBogen Therapeutics
15.4 AstraZeneca
15.5 Biond Biologics
15.6 BridgeBio Oncology Therapeutics
15.7 Bristol Myers Squibb
15.8 Boehringer Ingelheim
15.9 Eli Lilly
15.10 Erasca
15.11 Frontier Medicines
15.12 GenFleet Therapeutics
15.13 Innovent Bio
15.14 Jacobio Pharmaceuticals
15.15 Jiangsu Hansoh Pharmaceutical
15.16 Jiangsu Hengrui Medicine Co.
15.17 Quanta Therapeutics
15.18 Revolution Medicines
15.19 Roche
15.20 Suzhou Zelgen Biopharmaceuticals

List of Figures
Figure 1-1: RAS Mutation - Frequency of KRAS Mutation v/s HRAS and NRAS Mutations
Figure 1-2: KRAS Inhibitors - Development Milestones
Figure 1-3: KRAS Inhibitor - General Mechanism In Cancer
Figure 1-4: KRAS Inhibitors - Targeting Approaches
Figure 1-5: Direct Targeting of Mutant KRAS
Figure 1-6: Targets for Modifying the KRAS Membrane Association
Figure 2-1: KRAS Mutational Frequency By Organ (%)
Figure 2-2: KRAS Inhibitor - Role In Cancer Treatment
Figure 3-1: Approved KRAS Inhibitors
Figure 3-2: Global - KRAS Inhibitors Sales (US$ Million), 2021-2024
Figure 3-3: Global - KRAS Inhibitors Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 3-4: KRAS Inhibitor Market - Future Opportunities
Figure 3-5: Global - KRAS Inhibitors Sales (US$ Million), 2025-2030
Figure 4-1: Sotorasib - Approval Year By Indication
Figure 4-2: Sotorasib - Patent Expiration Year
Figure 4-3: US - Cost Per Unit and Supply Of Lumakras (US$), April’2025
Figure 4-4: EU - Cost Per Unit and Supply Of Lumakras (US$), April’2025
Figure 4-5: Lumakras - Recommended Dose Reduction Levels For Adverse Reaction
Figure 4-6: Global - Lumakras/Lumykras Annual Sales (US$ Million), 2021-2024
Figure 4-7: Global - Lumakras/Lumykras Sales (US$ Million), Q1-Q4’2024
Figure 4-8: Regional - US v/s ROW Lumakras/Lumykras Sales (US$ Million), 2024
Figure 4-9: Regional - US v/s ROW Lumakras/Lumykras Sales (%), 2024
Figure 4-10: US - Lumakras Sales (US$ Million), 2021-2024
Figure 4-11: US - Lumakras Sales (US$ Million), Q1-Q4’2024
Figure 4-12: ROW - Lumakras/Lumykras Sales (US$ Million), 2021-2024
Figure 4-13: ROW - Lumakras/Lumykras Sales (US$ Million), Q1-Q4’2024
Figure 5-1: Krazati - Approval Year By Indication
Figure 5-2: Krazati - Market Exclusivity Expiry By Region
Figure 5-3: US - Cost Per Unit and Supply Of Krazati (US$), April’2025
Figure 5-4: Krazati - Recommended Dosage Reduction for Adverse Reactions (mg/day)
Figure 5-5: Global - Krazati Annual Sales (US$ Million), 2023-2024
Figure 5-6: Global - Krazati Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 5-7: Regional - US v/s ROW Krazati Sales (US$ Million), 2024
Figure 5-8: Regional - US v/s ROW Krazati Sales (%), 2024
Figure 5-9: US - Krazati Sales (US$ Million), Q1-Q4’2024
Figure 5-10: ROW - Krazati Sales (US$ Million), Q1-Q4’2024
Figure 7-1: Garsorasib - NMPA Breakthrough Therapy Designation Year By Indication
Figure 9-1: TBBO8520-101 Phase 1 Study (NCT06343402) - Initiation and Completion Year
Figure 9-2: KRYSTAL-12 Phase 3 Study (NCT04685135) - Initiation and Completion Year
Figure 9-3: RAMP203/VS-6766-203 Phase 1/2 Study (NCT05074810) - Initiation and Completion Year
Figure 9-4: RASolve 301 Phase 3 (NCT06881784) Study - Initiation and Completion Year
Figure 9-5: RMC-LUNG-101 Phase 1/2 (NCT06162221) Study - Initiation and Completion Year
Figure 9-6: CodeBreaK 301 Phase 3 (NCT06252649) Study - Initiation and Completion Year
Figure 9-7: CodeBreaK 101 Phase 3 (NCT04185883) Study - Initiation and Completion Year
Figure 9-8: KRYSTAL-10 Phase 3 (NCT04793958) Study - Initiation and Completion Year
Figure 9-9: RMC-6291-101 Phase 1 (NCT06128551) Study - Initiation and Completion Year
Figure 9-10: RMC-6236-001 Phase 1 (NCT05379985) Study - Initiation and Completion Year
Figure 9-11: RMC-9805-001 Phase 1 (NCT06040541) Study - Initiation and Completion Year
Figure 9-12: BrainMet ADePPT Phase 1 (NCT06807619) Study - Initiation and Completion Year
Figure 9-13: NCI-2023-09685 Phase 1 (NCT06130254) Study - Initiation and Completion Year
Figure 10-1: Global - KRAS Protein Inhibitors Clinical Trials By Country, 2025 -2030
Figure 10-2: Global - KRAS Protein Inhibitors Clinical Trials By Phase, 2025 -2030
Figure 10-3: Global - KRAS Protein Inhibitors Clinical Trials By Company, 2025 -2030
Figure 10-4: Global - KRAS Protein Inhibitors Clinical Trials By Indication, 2025 -2030
Figure 10-5: Global - KRAS Protein Inhibitors Clinical Trials By Priority Status, 2025 -2030
Figure 13-1: KRAS inhibitors and Immunotherapy Combinations
Figure 14-1: KRAS Inhibitors Market - Drivers
Figure 14-2: KRAS Inhibitors Market - Challenges

List of Tables
Table 3-1: KRAS Inhibitors Breakthrough Therapy, Fast Track and Orphan Designation
Table 4-1: Lumakras - Recommended Dosage Modifications For Adverse Reactions
Table 5-1: Krazati - Recommended Dosage Modifications For Adverse Reactions
Table 8-1: US - Ongoing KRAS Inhibitor Clinical Trials
Table 8-2: China - Ongoing KRAS Inhibitor Clinical Trials
Table 8-3: UK - Ongoing KRAS Inhibitor Clinical Trials
Table 8-4: Japan - Ongoing KRAS Inhibitor Clinical Trials
Table 8-5: South Korea - Ongoing KRAS Inhibitor Clinical Trials
Table 8-6: Canada - Ongoing KRAS Inhibitor Clinical Trials
Table 8-7: Taiwan - Ongoing KRAS Inhibitor Clinical Trials
Table 8-8: Australia - Ongoing KRAS Inhibitor Clinical Trials
Table 9-1: Lung Cancer - KRAS Inhibitors In Clinical Trials
Table 9-2: Colorectal Cancer - KRAS Inhibitors In Clinical Trials
Table 9-3: Colorectal Cancer - KRAS Inhibitors With Regulatory Designations
Table 9-4: Pancreatic Cancer - KRAS Inhibitors in Clinical Trials
Table 9-5: Pancreatic Cancer - KRAS Inhibitors with Regulatory Designations
Table 13-1: KRAS Inhibitor and Immunotherapy Combinations In Clinical Trials
Table 13-2: KRAS Inhibitor and Chemotherapy Combinations In Clinical Trials
Table 13-3: KRAS Inhibitor and Targeted Therapy Combinations In Clinical Trials
Table 13-4: KRAS Inhibitor and Radiotherapy Combinations In Clinical Trials